Register
Journal Updates
eMediNexus Coverage from: 
Autoinjectable testosterone now available for the first time
eMediNexus,  03 October 2018
remove_red_eye 760 Views
#Pathology and Lab Medicine #Pharmacist #Urology

0 Read Comments                

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection (50 mg, 75 mg, and 100 mg) for testosterone replacement therapy in men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone. It is the first FDA-approved subcutaneous testosterone enanthate product for once-weekly self-administration using a disposable autoinjector.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!